hotspot -WSS

hotspot

author：explore 2025-09-28 23:47:36 - browse：24

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Elevance, SCAN deals highlight health insurer acquisition scrutiny

WSS

FDA has safety concerns on CRISPR

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

FDA has safety concerns on CRISPR

New CMS data security rules will hurt Medicare, Medicaid research

Readout Newsletter: XBI biotech index, Akero Therapeutics

The FDA weighs the risks of candy

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

entertainment

How one medical school became remarkably diverse

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

The high cost of giving birth even with insurance

Why Sanofi got shellacked over its spinoff

At least 13 dead in Texas as scorching temps continue

Obamacare plans could cover weight loss drugs

Medical leaders decry Supreme Court decision on affirmative action

Congress may force more Covid

Heart attack and stroke risk calculators need revising

Surprise medical billing ban raises prices elsewhere

leisure time

Reporting on presidential health from Reagan to Trump and Biden

Flagship Pioneering startup Sonata Therapeutics lays off 21

Diversifying clinical trials isn't enough to close racial gaps: study

Medtronic CEO on promising devices for diabetes, hypertension

WATCH: Why do our ears pop?

New CMS data security rules will hurt Medicare, Medicaid research

entertainment

hotspot

hotspot

Wikipedia